临床基础研究的进展:帕金森病的表现,治疗和机制
Ting-Ting Yang1, Yu-Cong Liu1, Jing Li1
1Department of Anesthesiology Zunyi Medical University Zunyi Guizhou China.
Ibrain
|October 3, 2023
概括
帕金森病 (PD) 中的神经元损失导致条纹损伤和运动缺陷. 研究正在探索这种神经退行性疾病的生物标志物和治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
背景情况:
- 帕金森病 (PD) 涉及黑体中神经元的损失,导致条纹性损伤和多巴胺缺乏.
- 关键的神经病理特征包括α-Synuclein聚合和外围自主神经系统功能障碍.
- 非运动症状越来越被认可,可能会增加疾病风险.
研究的目的:
- 为了审查帕金森病的分子病原性.
- 讨论诊断生物标志物和神经成像技术的进展.
- 概述目前和新兴的帕金森病治疗策略.
主要方法:
- 关于帕金森病病因,诊断和治疗的文献综述.
- 分析神经成像技术,如SPECT和MRI用于诊断.
- 检查药物和非药物治疗选择.
主要成果:
- 多种途径,包括α-Synuclein,神经元平衡,线粒体功能,氧化应激和神经炎症,有助于PD的发病.
- 神经成像技术在促进差异诊断方面表现有前途.
- 药物治疗,包括多巴胺替代和症状管理,至关重要.
结论:
- 了解复杂的分子病原体是开发有效帕金森病治疗的关键.
- 先进的神经成像帮助在早期和准确的诊断.
- 结合药理疗法和症状管理的多方面的方法可以改善患者的治疗结果.
相关概念视频
Parkinson's Disease: Overview
590
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
590
Parkinson's Disease: Treatment
292
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
292
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Clinical Trials
6.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.8K
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K


